Risk Reducing Salpingectomy With Delayed Oophorectomy as an Alternative to Risk- Reducing Salpingo-oophorectomy in High Risk-Women to Assess the Safety of Prevention - US Cohort Study

Description

This is a prospective preference study that will evaluate non-inferiority of the innovative treatment (RRS with delayed RRO) as compared to the standard treatment (RRSO) with respect to high grade serous (ovarian) cancer incidence

Conditions

Ovarian Cancer, Fallopian Tube Cancer

Talk to us

Study Overview

On this page

Study Details

Study overview

This is a prospective preference study that will evaluate non-inferiority of the innovative treatment (RRS with delayed RRO) as compared to the standard treatment (RRSO) with respect to high grade serous (ovarian) cancer incidence

Risk Reducing Salpingectomy With Delayed Oophorectomy as an Alternative to Risk- Reducing Salpingo-oophorectomy in High Risk-Women to Assess the Safety of Prevention - US Cohort Study

Risk Reducing Salpingectomy With Delayed Oophorectomy as an Alternative to Risk- Reducing Salpingo-oophorectomy in High Risk-Women to Assess the Safety of Prevention - US Cohort Study

Condition
Ovarian Cancer
Intervention / Treatment

-

Contacts and Locations

Boston

Harvard Cancer Center, Boston, Massachusetts, United States, 02215

Saint Louis

Washington University School of Medicine, Saint Louis, Missouri, United States, 63130

Houston

M D Anderson Cancer Center, Houston, Texas, United States, 77030

Seattle

Fred Hutch/University of Washington/Seattle Children's Cancer Consortium, Seattle, Washington, United States, 98195

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • 1. Premenopausal women with a documented deleterious mutation in BRCA1, BRCA2, BRIP1, RAD51C and/or RAD51D gene germline mutation.
  • 2. Age 25-40 years for BRCA1 mutation carriers, 25-45 years for BRCA2 and 30-50 years for BRIP1, RAD51C, RAD51D
  • 3. Childbearing completed or no longer requires fallopian tubes
  • 4. Presence of at least one fallopian tube
  • 5. Participants may have a personal history of non-ovarian malignancy.
  • 6. Informed consent must be obtained and documented.
  • 1. Postmenopausal status (natural menopause or due to (cancer) treatment)
  • 2. Wish for second stage RRO within two years after RRS (if clear at enrollment)
  • 3. Legally incapable
  • 4. Prior bilateral salpingectomy
  • 5. A personal history of ovarian, fallopian tube or peritoneal cancer
  • 6. Current clinicals signs, diagnosis or treatment for malignant disease

Ages Eligible for Study

18 Years to

Sexes Eligible for Study

FEMALE

Accepts Healthy Volunteers

No

Collaborators and Investigators

M.D. Anderson Cancer Center,

Roni Wilke, MD, PRINCIPAL_INVESTIGATOR, M.D. Anderson Cancer Center

Study Record Dates

2026-12-26